Dyne Therapeutics, Inc. (DYN) News
Follow Dyne Therapeutics, Inc. (DYN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 39 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Dyne Therapeutics Q3 Net Loss Widens on Higher Trial Costs
EQUITY | Nov 05, 2026, 12:48 PM UTC
M
Dyne Therapeutics Reports $193.6 Million Q3 Net Loss
Dyne reported a Q3 2026 net loss of $193.6 million, or $1.06 per share, versus a $108.0 million loss, or $0.76 per share, in Q3 2025. Cash and marketable securities totaled $1.134 billion at September 30, 2026, and are e
EQUITY | Nov 05, 2026, 12:45 PM UTC
M
Dyne Therapeutics Reports Third-Quarter 2026 Financial Results
The report lists a Biologics License Application for z-rostudirsen in exon 51 Duchenne muscular dystrophy among recent business highlights.
EQUITY | Nov 05, 2026, 12:32 PM UTC
L
Dyne Therapeutics Price Target Maintained With a $38.00/Share by Chardan Capital
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 12:10 PM UTC
L
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target
Chardan Capital maintained their Buy rating on Dyne Therapeutics's stock with a price target of $38.00.The price target implies an upside of 134.4% from the Sep 29 close of $16.21.Key takeaways from the analyst notePromi
EQUITY | Sep 30, 2026, 12:00 PM UTC
L
Dyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga: GMT) Dyne Therapeutics Price Target Cut to $32.00/Share From $50.00 by HC Wainwright & Co.Ratings actions from Benzinga
NEWS | Sep 30, 2026, 10:28 AM UTC
L
HC Wainwright & Co. maintains Buy rating on Dyne Therapeutics, $32 price target
HC Wainwright & Co. maintained their Buy rating on Dyne Therapeutics's stock with a price target of $32.00.The price target implies an upside of 97.4% from the Sep 29 close of $16.21.Key takeaways from the analyst noteSt
EQUITY | Sep 30, 2026, 10:18 AM UTC
L
Dyne reports 1-year ACHIEVE pooled data showing vHOT -3.2s at 6m, functional and strength gains at 12m
Dyne announced one-year pooled ACHIEVE MAD data showing a 3.2s vHOT improvement at 6 months and sustained functional and strength gains at 12 months.Key Highlights:Original SEC Filing: Dyne Therapeutics, Inc. [ DYN ] - 8
REGULATION | Sep 29, 2026, 08:15 PM UTC
L
Dyne Therapeutics, Inc. (DYN) Shows 12-Month Functional Gains in DM1; REC Topline Expected Q1 2027
Dyne Therapeutics reported 12-month pooled MAD data for z-basivarsen (DYNE-101) in DM1 showing functional improvement vs baseline, placebo and a matched natural history cohort. The REC’s primary endpoint is 6-month vHOT;
NEWS | Sep 29, 2026, 08:08 PM UTC
L
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history
NEWS | Sep 29, 2026, 08:08 PM UTC
L
Dyne Therapeutics Price Target Maintained With a $47.00/Share by Piper Sandler
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 05:56 PM UTC
L
DYN: Expect major regulatory and clinical milestones in DMD and DM1, with commercial launch preparations underway
The company highlighted its differentiated genetic medicine platform, strong clinical data in DMD and DM1, and readiness for commercial launch. Key catalysts include a major regulatory decision in January, pivotal DM1 da
NEWS | Sep 15, 2026, 04:17 PM UTC
L
DYN: Upcoming FDA decision and pivotal data could establish a new standard in muscle disease therapy
A novel platform enables safe, broad delivery of genetic medicines for muscle diseases, with clinical data showing functional improvements in DMD and DM1. Key catalysts include an upcoming FDA decision, pivotal data read
REGULATION | Sep 15, 2026, 03:59 PM UTC
L
Morgan Stanley keeps Dyne Therapeutics at Overweight
Morgan Stanley maintained a Overweight rating on Dyne Therapeutics.
EQUITY | Sep 09, 2026, 05:38 PM UTC
L
Dyne Therapeutics shares fall after Novartis Phase 3 setback
Dyne Therapeutics (DYN) shares extended their sell-off on Wednesday, trading 4.2% lower as Wall Street weighed risks to its experimental muscle-disease drug after Novartis’ Phase 3 setback.
EQUITY | Sep 09, 2026, 03:42 PM UTC
L
JP Morgan cuts Dyne Therapeutics rating to Underweight
JP Morgan cut Dyne Therapeutics’ rating to Underweight from Neutral, according to Benzinga.
EQUITY | Sep 09, 2026, 03:09 PM UTC
L
Dyne Therapeutics price target cut to $30 from $35 at RBC Capital
RBC Capital cut its Dyne Therapeutics price target to $30.00 per share from $35.00, according to a Benzinga ratings action roundup.
EQUITY | Sep 09, 2026, 01:38 PM UTC
L
Baird cuts Dyne Therapeutics price target to $26 from $30
Baird cut its Dyne Therapeutics price target to $26.00 per share from $30.00, per Benzinga ratings actions.
EQUITY | Sep 09, 2026, 01:34 PM UTC
L
Dyne Therapeutics slides after J.P. Morgan downgrade tied to Novartis setback
Dyne Therapeutics (DYN) traded lower in premarket after J.P. Morgan downgraded the neuromuscular disease company, citing a study setback affecting a Novartis (NVS) medicine and share pressure in the prior session.
EQUITY | Sep 09, 2026, 01:21 PM UTC
M
Dyne and Sarepta shares slump as Novartis trial setback hits muscle disease stocks
Shares of Dyne Therapeutics (DYN) and Sarepta (SRPT) fell Tuesday after Novartis’ NOT treatment for a muscle-wasting disorder failed in a trial, raising concerns about similar therapies for a rare disease.
EQUITY | Sep 08, 2026, 05:00 PM UTC
L
Dyne Therapeutics to present additional Phase 1/2 trial data
Dyne Therapeutics plans to present additional one-year Phase 1/2 ACHIEVE trial data for z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1) at upcoming medical meetings.
EQUITY | Sep 08, 2026, 11:51 AM UTC
L
Dyne Therapeutics to present preclinical DMD data at NMSG meeting
Dyne Therapeutics plans to present preclinical data for multiple DMD candidates at the 27th Annual NMSG Scientific Meeting. The data support four investigational therapies targeting exon skipping 53, 45, 44 or 55, advanc
EQUITY | Sep 03, 2026, 11:39 AM UTC
L
Dyne Therapeutics to present preclinical data at NMSG meeting
Dyne Therapeutics plans to present preclinical data for multiple DMD development candidates at the 27th Annual NMSG Scientific Meeting.
EQUITY | Sep 03, 2026, 11:30 AM UTC
L
Dyne Therapeutics to participate in upcoming investor conferences
Dyne Therapeutics said management is scheduled to participate in upcoming investor conferences.
EQUITY | Sep 02, 2026, 11:37 AM UTC
L
DYN - Dyne Therapeutics to Participate in Upcoming Investor Conferences
DYN - Dyne Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:30 AM UTC
L
Dyne Therapeutics reports inducement grants under Nasdaq rule
Dyne Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 20, 2026, 08:05 PM UTC
H
RBC Reiterates DYN Outperform
RBC raises DYN price target to $35
EQUITY | Jul 30, 2026, 11:13 AM UTC
L
DYN - Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
DYN - Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
EARNINGS | Jul 29, 2026, 08:30 PM UTC
L
Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial
Dyne Therapeutics...
REGULATION | Jul 28, 2026, 11:41 AM UTC
L
DYN new Overweight @ Cantor
DYN new Overweight @ Cantor
EQUITY | Jul 23, 2026, 12:08 PM UTC
L
DYN Initiated Overweight at Cantor Fitzgerald
DYN Initiated Overweight at Cantor Fitzgerald
EQUITY | Jul 23, 2026, 11:55 AM UTC
L
Today's priced deal • DYN 18.3M share Spot Secondary, priced at $20.50, by MSCO, JEFF, Evercore, LifeSci, RAJA & Jones
Today's priced deal • DYN 18.3M share Spot Secondary, priced at $20.50, by MSCO, JEFF, Evercore, LifeSci, RAJA & Jones
EQUITY | Jul 22, 2026, 12:59 PM UTC
L
DYN priced an upsized public stock offering, raising about $375M through the sale of 18.3M shares at $20.50 each, up from its initially prop
DYN priced an upsized public stock offering, raising about $375M through the sale of 18.3M shares at $20.50 each, up from its initially proposed $300M raise; shares -9.5% premarket
EQUITY | Jul 22, 2026, 10:30 AM UTC
H
Closing Bell Movers: Finward jumps after First Financial deal
Stock futures were sharply higher in after-hours, adding to the session's broad gains. Traders after the close saw early reporting mostly from smaller banks, though notable names included Capital One, Bank OZK, and Pegas
EARNINGS | Jul 21, 2026, 10:05 PM UTC
L
DYN -7% post mkt after offering headlines
DYN -7% post mkt after offering headlines
EQUITY | Jul 21, 2026, 08:48 PM UTC
L
DYN Dyne Therapeutics announces proposed public offering of common stock
DYN Dyne Therapeutics announces proposed public offering of common stock
EQUITY | Jul 21, 2026, 08:47 PM UTC
L
Dyne Therapeutics announces FDA acceptance of zeleciment rostudirsen BLA
Dyne Therapeutics...
REGULATION | Jul 20, 2026, 11:33 AM UTC
L
DYN Dyne Therapeutics announces U.S. FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dy
DYN Dyne Therapeutics announces U.S. FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dystrophy (dmd) Dyne Therapeutics, - FDA grants priority review with pdufa date Ja
REGULATION | Jul 20, 2026, 11:30 AM UTC
M
BDC: BUY @ Citi
Citi initiates BDC with a BUY rating, among other top initiations
EQUITY | Jun 26, 2026, 11:17 AM UTC